Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis

Transplant Proc. 1997 Feb-Mar;29(1-2):627-8. doi: 10.1016/s0041-1345(96)00363-6.

Authors

H Reichenspurner¹, P Gamberg, M Nitschke, H Valantine, S Hunt, P E Oyer, B A Reitz

Affiliation

¹ Department of Cardiothoracic Surgery and Medicine, Stanford University, California, USA.

PMID: 9123449
DOI: 10.1016/s0041-1345(96)00363-6

No abstract available

Publication types

Clinical Trial
Controlled Clinical Trial

MeSH terms

Adult
Aerosols
Amphotericin B / administration & dosage
Amphotericin B / therapeutic use*
Antifungal Agents / administration & dosage
Antifungal Agents / therapeutic use*
Aspergillosis / epidemiology
Aspergillosis / prevention & control*
Candidiasis / epidemiology
Candidiasis / prevention & control*
Female
Follow-Up Studies
Heart Transplantation*
Heart-Lung Transplantation*
Humans
Incidence
Lung Transplantation*
Male
Postoperative Complications*
Time Factors

Substances

Aerosols
Antifungal Agents
Amphotericin B